TG Therapeutics Inc (NASDAQ:TGTX) announced the publication of preclinical data describing the synergy of the Company’s next generation, once daily, PI3K-delta inhibitor, TGR-1202, …
TG Therapeutics, Inc. (NASDAQ:TGTX) announced the launch of a Phase 1/2 study to evaluate the safety and efficacy of TGR-1202, the Company’s oral PI3K …
TG Therapeutics Inc (NASDAQ:TGTX) shares crashed almost 17% yesterday on back of the biotech firm’s announcement that it has filed with the FDA …
TG Therapeutics, Inc. (NASDAQ:TGTX) announced that it has filed with the FDA an amended protocol for the GENUINE Phase 3 trial.
TG Therapeutics Inc (NASDAQ:TGTX) announced that the U.S.
TG Therapeutics, Inc. (NASDAQ:TGTX) announced that the U.
TG Therapeutics Inc (NASDAQ:TGTX) announced the enrollment of its first patient in its registration-directed UNITY-DLBCL Phase 2b clinical study evaluating TG-1101, the Company’s novel …
TG Therapeutics Inc (NASDAQ:TGTX), announced that as part of a broader agreement with Jubilant Biosys (“Jubilant”), an Indian biotechnology company, TG Therapeutics entered into a …
TG Therapeutics Inc (NASDAQ:TGTX) announced the opening of its Phase 2 clinical study of TG-1101 (ublituximab), the Company’s glycoengineered anti-CD20 monoclonal antibody, in patients …
TG Therapeutics Inc (NASDAQ:TGTX) announced its key corporate goals and objectives for 2016, which include the following: Aggressively recruit into the GENUINE Phase 3 …
